Research and Markets: Global Systemic Lupus Erythematosus and Lupus Nephritis Drug Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/cb9kjf/pharmapoint) has announced the addition of the "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022" report to their offering.

Sales for SLE and LN by Region, 2012-2022

2012 Systemic Lupus Erythematosus (SLE) drug sales to be over $473.6m across the seven major markets covered in this report: US, France, Germany, Italy, Spain, UK and Japan. By the end of the forecast period in 2022, sales will grow to over $1.1 billion with a CAGR of 9.36%.

Focusing on Lupus Nephritis (LN), The authors estimates 2012 drug sales to be over $216.6m across the seven major markets covered in this report. By the end of the forecast period in 2022, sales will grow to over $505.9m with a CAGR of 8.86%.

The growth in the SLE and LN therapeutics will be driven by:

- Increasing uptake of biologics, including GlaxoSmithKline's Benlysta (belimumab), the only approved biologic for SLE, and off-label use of Roche's Rituxan

- The launch of Benlysta in Japan in 2016

- The launch of new biologic drugs during the second half of the forecast period

- The increasing number of prevalent cases of SLE and LN

The uptake of new biologic drugs that will enter the SLE and LN markets will be initially low. Biologic drugs will primarily target lupus patients with high disease activity (approximately 10%-15% of all SLE patients) and therefore, currently marketed biologic drugs and new entrants will compete for a small segment of the total SLE patient population. This view is based on the available clinical trial data to date for Benlysta, the clinical trial design for current pipeline products and The authors's primary research (conducted in July-August 2013).

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Opportunity and Unmet Need

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

Companies Mentioned

  • GlaxoSmithKline
  • Roche
  • UCB
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • Anthera Pharmaceuticals
  • ImmuPharma
  • Merck Serono

For more information visit http://www.researchandmarkets.com/research/cb9kjf/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders